{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=E+coli+vaccine+2&page=2",
    "query": {
      "intervention": "E coli vaccine 2",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 30,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=E+coli+vaccine+2&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=E+coli+vaccine+2&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T20:00:07.736Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03576183",
      "title": "Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Enterotoxigenic Escherichia Coli Infection",
        "Diarrhea"
      ],
      "interventions": [
        {
          "name": "VLA1701",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Challenge Strain",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Valneva Austria GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 34,
      "start_date": "2018-06-04",
      "completion_date": "2018-11-30",
      "has_results": true,
      "last_update_posted_date": "2021-04-23",
      "last_synced_at": "2026-10-09T20:00:07.736Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03576183"
    },
    {
      "nct_id": "NCT01556945",
      "title": "Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malaria, Falciparum"
      ],
      "interventions": [
        {
          "name": "FMP1/AS02",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RTS,S/AS02",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AS02 adjuvant alone",
          "type": "OTHER"
        },
        {
          "name": "Malaria challenge",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 72,
      "start_date": "2001-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-05-02",
      "last_synced_at": "2026-10-09T20:00:07.736Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01556945"
    },
    {
      "nct_id": "NCT00133484",
      "title": "UMD rPA Regimen Trial in Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bacillus Anthracis (Anthrax)"
      ],
      "interventions": [
        {
          "name": "Anthrax vaccine absorbed made from Bacillus anthracis (AVA)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant protein antigen (rPA) made from Bacillus anthrax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant protein antigen (rPA) made from Escherichia coli",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 270,
      "start_date": null,
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-10-09T20:00:07.736Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Durham, North Carolina",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00133484"
    },
    {
      "nct_id": "NCT02531685",
      "title": "Phase 1 Study of dmLT ID Vaccination in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastroenteritis Escherichia Coli"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 100,
      "start_date": "2016-06-02",
      "completion_date": "2020-05-04",
      "has_results": false,
      "last_update_posted_date": "2020-10-26",
      "last_synced_at": "2026-10-09T20:00:07.736Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02531685"
    },
    {
      "nct_id": "NCT04899336",
      "title": "A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention"
      ],
      "interventions": [
        {
          "name": "ExPEC9V",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 17797,
      "start_date": "2021-06-30",
      "completion_date": "2025-08-27",
      "has_results": true,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-09T20:00:07.736Z",
      "location_count": 142,
      "location_summary": "Guntersville, Alabama • Phoenix, Arizona • Sun City West, Arizona + 100 more",
      "locations": [
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City West",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04899336"
    },
    {
      "nct_id": "NCT02052934",
      "title": "Safety of Sublingual dmLT for ETEC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastroenteritis Escherichia Coli"
      ],
      "interventions": [
        {
          "name": "Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 80,
      "start_date": "2014-03-10",
      "completion_date": "2016-11-02",
      "has_results": false,
      "last_update_posted_date": "2019-01-28",
      "last_synced_at": "2026-10-09T20:00:07.736Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02052934"
    },
    {
      "nct_id": "NCT00850668",
      "title": "Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Food Hypersensitivity",
        "Hypersensitivity",
        "Immediate Hypersensitivity",
        "Peanut Hypersensitivity"
      ],
      "interventions": [
        {
          "name": "E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Allertein Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 15,
      "start_date": "2009-10",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2013-05-27",
      "last_synced_at": "2026-10-09T20:00:07.736Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • New York, New York",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00850668"
    },
    {
      "nct_id": "NCT04634513",
      "title": "Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Shigella Infection",
        "Enterotoxigenic Escherichia Coli Infection"
      ],
      "interventions": [
        {
          "name": "strain CVD 1208S-122",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 53,
      "start_date": "2022-09-29",
      "completion_date": "2024-10-01",
      "has_results": true,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-10-09T20:00:07.736Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04634513"
    },
    {
      "nct_id": "NCT04090528",
      "title": "pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration-resistant Prostate Cancer",
        "Metastatic Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "pTVG-HP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pTVG-AR",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2019-10-21",
      "completion_date": "2027-03",
      "has_results": true,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-10-09T20:00:07.736Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Madison, Wisconsin",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04090528"
    },
    {
      "nct_id": "NCT00516659",
      "title": "ETEC Logistics Trial (TREK)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diarrhea"
      ],
      "interventions": [
        {
          "name": "Heat-Labile Enterotoxin of Escherichia coli (LT)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Intercell USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 201,
      "start_date": "2006-05",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2012-03-14",
      "last_synced_at": "2026-10-09T20:00:07.736Z",
      "location_count": 13,
      "location_summary": "Long Beach, California • Chicago, Illinois • Baltimore, Maryland + 9 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00516659"
    }
  ]
}